About aim immunotech - AIM
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
AIM At a Glance
AIM ImmunoTech, Inc.
2117 SW Highway 484
Ocala, Florida 34473
| Phone | 1-352-448-7797 | Revenue | 202.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -28,962,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 43.262% | |
| Fiscal Year-end | 12 / 2024 | Employees | 26 | |
| View SEC Filings |
AIM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 105.806 |
| Price to Book Ratio | 2.263 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.307 |
| Enterprise Value to Sales | 48.068 |
| Total Debt to Enterprise Value | 0.074 |
AIM Efficiency
| Revenue/Employee | 7,769.231 |
| Income Per Employee | -1,113,923.077 |
| Receivables Turnover | 0.171 |
| Total Asset Turnover | 0.005 |
AIM Liquidity
| Current Ratio | 1.682 |
| Quick Ratio | 1.682 |
| Cash Ratio | 1.511 |
AIM Profitability
| Gross Margin | -38.614 |
| Operating Margin | -15,793.069 |
| Pretax Margin | -14,337.624 |
| Net Margin | -14,337.624 |
| Return on Assets | -64.838 |
| Return on Equity | -118.936 |
| Return on Total Capital | -264.445 |
| Return on Invested Capital | -116.183 |
AIM Capital Structure
| Total Debt to Total Equity | 7.016 |
| Total Debt to Total Capital | 6.556 |
| Total Debt to Total Assets | 3.698 |
| Long-Term Debt to Equity | 5.186 |
| Long-Term Debt to Total Capital | 4.52 |